Johnson & Johnson has submitted its first marketing application for nipocalimab, seeking approval for the FcRn blocker in generalised myasthenia gravis (gMG), where it would compete wit
Johnson & Johnson has reported new phase 3 data with its FcRn blocker nipocalimab in generalised myasthenia gravis (gMG), pointing to data that it says differentiates it from other drug
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
